DAXX-inducing phytoestrogens inhibit ER+ tumor initiating cells and delay tumor development

• Published in: NPJ breast cancer 2020-08, Vol.6 (1), p.37-37, Article 37
• Main Authors: Peiffer, Daniel S., Ma, Emily, Wyatt, Debra, Albain, Kathy S., Osipo, Clodia
• Format: Article
• Language: English
• Subjects: 631/67/1347; 631/67/71; Biomedical and Life Sciences; Biomedicine; Breast cancer; Cancer Research; Cell Biology; Cell growth; Endocrine therapy; Estrogens; Gene expression; Human Genetics; Medical prognosis; Oncology; Protein expression; Proteins
• ISSN: 2374-4677; 2374-4677
• DOI: 10.1038/s41523-020-00178-5

Recurrence of estrogen receptor (ER)-positive breast tumors despite curative-intent adjuvant therapy is thought to be due to enrichment of tumor initiating cells (TIC) during endocrine therapy (ET). Recently, it was identified that by antagonizing the ER, ET promotes rapid degradation of the death-associated factor 6 (DAXX) protein, which is necessary and sufficient to potently inhibit TICs. Thus, the goal of the current study was to identify a DAXX-inducing agent to inhibit TICs and prevent proliferation of the tumor. Phytoestrogens (naringenin, resveratrol, genistein, apigenin, and quercetin) were screened for DAXX protein expression, anti-TIC and anti-proliferative efficacy in vitro and in vivo. Specific DAXX-inducing phytoestrogens were tested to assess selectivity towards ERα and/or ERβ. Results showed that phytoestrogens tested induced DAXX protein expression and inhibited survival of TICs from ER+ MCF-7 and T47D cells. Only naringenin, resveratrol, and quercetin did not stimulate total cell proliferation. Naringenin, resveratrol, but not quercetin inhibited survival of TICs in vitro and in vivo in a DAXX-dependent manner. Naringenin-induced DAXX protein expression and inhibition of TICs seemed to be more selective towards ERβ while resveratrol was more selective through ERα. Naringenin or resveratrol inhibited the rate of tumor initiation and rate of tumor growth in a DAXX-dependent manner. These results suggest that a therapeutic approach using a phytoestrogen to induce DAXX protein expression could potently inhibit TICs within a tumor to delay or prevent tumor initiation. Therefore, a DAXX-promoting phytoestrogen should be explored for prevention of tumor progression in advanced disease and relapse in the adjuvant setting.